Dr. Reddy's Laboratories Ltd. Form 6-K Filing

This Form 6-K filing from Dr. Reddy's Laboratories Limited reports on a news article published on March 10, 2026, regarding a Delhi High Court ruling. The court allowed Dr. Reddy's to manufacture Semaglutide for export to countries where Novo Nordisk does not hold a patent. This decision upholds a previous order, refusing an interim injunction sought by Novo Nordisk. The company clarifies that this matter is ongoing and sub-judice, and no material event requiring further disclosure under SEBI Listing Regulations has occurred at this stage. The filing references articles from Business Standard and other media outlets. The company is incorporated in India and its principal executive office is located in Hyderabad.